Prevalence and Predictors of Pap Smear Cervical Epithelial Cell Abnormality among HIV-Positive and Negative Women Attending Gynecological Examination in Cervical Cancer Screening

Background: Cervical cancer is the leading cause of cancer related death among women in developing countries. Cervical cancer is preceded by cervical surface epithelial cell abnormalities (ECA) which can be detected by Pap smear test. Simultaneous human papillomavirus and human immunodeficiency virus (HIV) infection increases cervical cancer. Data on the prevalence and predictors of ECA among women in Ethiopia is limited. Hence, we aimed to determine the prevalence and associated factors of ECA among women. Methods: A comparative cross-sectional study was conducted among HIV+ and HIVwomen attending gynecological examination in cervical cancer screening center at the Debre Markos referral hospital. The study subjects were stratified by HIV status and systematic random sampling method was used to recruit study participants. Cervical smears were collected for Pap smear examination. Logistic regression analysis was employed to examine the possible risk factors of cervical ECA. Results: A total of 197 HIV+ and 194 HIVwomen were enrolled in the study. The overall prevalence of cervical ECA was 14.1 % of which the prevalence of atypical squamous cells undetermined significance (ASCUS), low grade squamous intraepithelial lesion (SIL), high grade SIL, squamous cell carcinoma and ASC, cannot exclude high grade SIL (ASCH) were 5.1, 3.8, 4.1 and 1.0 %, 0.0 % respectively. Significantly higher prevalence of ECA (17.8 %) was observed among HIV+ women (COR 1.9, 95 % CI: 1.1 − 3.4, p = 0.036) as compared to HIV-women (10.3 %). Multiple sexual partnership (AOR 3.2, 95 % CI: 1.1 − 10.0, p = 0.04), early ages of first sexual contact (<15 years) (AOR 5.2, 95 % CI: 1.5 − 17.9, p = 0.009), parity greater than three (AOR 10.9, 95 % CI: 4.2 − 16.8, p < 0.001) and long term oral contraceptive pills (OCP) use (AOR 11.9, 95 % CI: 2.1 − 16.7, p = 0.02) were significant predictors of prevalence of ECA. Conclusions: Cervical ECA is a major problem among HIV-infected women. Lower CD4+ T-cell counts of below 350 cells/μl, HIV infection, multiple sexual partnership, early age at first sexual contact, parity greater than three and long term OCP use were significant predictors of prevalence of ECA. Strengthening screening program in HIV+ women should be considered. * Correspondence: abezew@gmail.com Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia Full list of author information is available at the end of the article © 2015 Getinet et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Getinet et al. BMC Clinical Pathology (2015) 15:16 DOI 10.1186/s12907-015-0016-2

[1]  U. Jeschke,et al.  Prevalence of oral HPV infection in cervical HPV positive women and their sexual partners , 2019, Archives of Gynecology and Obstetrics.

[2]  C. Meijer,et al.  Early detection of CIN3 and cervical cancer during long‐term follow‐up using HPV/Pap smear co‐testing and risk‐adapted follow‐up in a locally organised screening programme , 2014, International journal of cancer.

[3]  M. Campagna,et al.  Prevalence and Molecular Epidemiology of Human Papillomavirus Infection in Italian Women with Cervical Cytological Abnormalities , 2014, Journal of public health research.

[4]  K. Sundström,et al.  Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review , 2014, Current opinion in oncology.

[5]  F. Buonaguro,et al.  Viral and Cellular Biomarkers in the Diagnosis of Cervical Intraepithelial Neoplasia and Cancer , 2013, BioMed research international.

[6]  A. Massinde,et al.  Prevalence and predictors of Cervical Intraepithelial Neoplasia among HIV infected women at Bugando Medical Centre, Mwanza-Tanzania , 2013, Infectious Agents and Cancer.

[7]  Richard D Moore,et al.  Invasive Cervical Cancer Risk Among HIV-Infected Women: A North American Multicohort Collaboration Prospective Study , 2013, Journal of acquired immune deficiency syndromes.

[8]  K. Richter,et al.  Age-specific prevalence of cervical human papillomavirus infection and cytological abnormalities in women in Gauteng Province, South Africa. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[9]  A. Hailu,et al.  Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study , 2013, BMC Cancer.

[10]  R. Friedman,et al.  Recurrence of cervical intraepithelial neoplasia in human immunodeficiency virus-infected women treated by means of electrosurgical excision of the transformation zone (LLETZ) in Rio de Janeiro, Brazil. , 2013, Sao Paulo medical journal = Revista paulista de medicina.

[11]  T. Akande,et al.  Prevalence and risk factors of cervical cancer among women in an urban community of Kwara State, north central Nigeria. , 2012, Journal of preventive medicine and hygiene.

[12]  Suelene B. N. Tavares,et al.  Cervical Cytopathology in a Population of HIV-Positive and HIV-Negative Women , 2012, Journal of tropical medicine.

[13]  B. Graubard,et al.  Prevalence of oral HPV infection in the United States, 2009-2010. , 2012, JAMA.

[14]  J. K. Roy,et al.  High prevalence of oncogenic HPV-16 in cervical smears of asymptomatic women of eastern Uttar Pradesh, India: A population-based study , 2012, Journal of Biosciences.

[15]  R. Ozercan,et al.  Evaluation of cervical cytological abnormalities in Turkish population. , 2012, Indian journal of pathology & microbiology.

[16]  E. Unger,et al.  Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. , 2011, The Journal of infectious diseases.

[17]  C. Komoltri,et al.  Prevalence and cumulative incidence of abnormal cervical cytology among HIV-infected Thai women: a 5.5-year retrospective cohort study , 2011, BMC infectious diseases.

[18]  G. Ergör,et al.  Cervical cancer risk levels in Turkey and compliance to the national cervical cancer screening standard. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[19]  B. AbdullGaffar,et al.  The prevalence of abnormal cervical cytology in women with infertility , 2010, Diagnostic cytopathology.

[20]  W. Banzhaf,et al.  Risk Factors for Cervical Precancer and Cancer in HIV-Infected, HPV-Positive Rwandan Women , 2010, PloS one.

[21]  D. Walmer,et al.  Prevalence and severity of cervical squamous intraepithelial lesion in a tertiary hospital in northern Tanzania. , 2010, Tanzania journal of health research.

[22]  P. Michelow,et al.  Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa , 2009, Cancer Causes & Control.

[23]  R. Biggar,et al.  Risk of human papillomavirus-associated cancers among persons with AIDS. , 2009, Journal of the National Cancer Institute.

[24]  V. Melo,et al.  Cervical intraepithelial neoplasia recurrence after conization in HIV‐positive and HIV‐negative women , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[25]  Y. Tettey,et al.  Cervical human papillomavirus infection in accra, ghana. , 2009, Ghana medical journal.

[26]  S. Batra,et al.  Human Papillomavirus Type 16 Variant Analysis of E6, E7, and L1 Genes and Long Control Region in Biopsy Samples from Cervical Cancer Patients in North India , 2008, Journal of Clinical Microbiology.

[27]  B. Thiers American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors , 2008 .

[28]  Robert P Fields Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. , 2008, The New England journal of medicine.

[29]  S. Shapiro,et al.  Cervical Human Papillomavirus (HPV) Infection in South African Women: Implications for HPV Screening and Vaccine Strategies , 2007, Journal of Clinical Microbiology.

[30]  S. Franceschi,et al.  Human papillomavirus and HPV vaccines: a review. , 2007, Bulletin of the World Health Organization.

[31]  Juana Santos,et al.  HUMAN PAPILLOMAVIRUS INFECTION AND CERVICAL CANCER: PATHOGENESIS AND EPIDEMIOLOGY , 2007 .

[32]  J. Palefsky CHAPTER 5 HPV infection and HPV‐associated neoplasia in immunocompromised women , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[33]  Helen Trottier,et al.  The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.

[34]  K. Ault Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract , 2006, Infectious diseases in obstetrics and gynecology.

[35]  N. Kiviat,et al.  Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. , 2006, Journal of the National Cancer Institute.

[36]  K. Anastos,et al.  Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. , 2005, JAMA.

[37]  C. Tremblay,et al.  Viral polymorphism in human papillomavirus types 33 and 35 and persistent and transient infection in the genital tract of women. , 2004, The Journal of infectious diseases.

[38]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[39]  Diane Solomon,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2003, Journal of lower genital tract disease.

[40]  Mark Sherman,et al.  The 2001 Bethesda System: terminology for reporting results of cervical cytology. , 2002, JAMA.

[41]  K. Shah,et al.  Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. , 2002, American journal of obstetrics and gynecology.

[42]  M. Kazatchkine,et al.  Increased Risk of Cervical Disease Among Human Immunodeficiency Virus–Infected Women With Severe Immunosuppression and High Human Papillomavirus Load , 2000, Obstetrics and gynecology.

[43]  T. Rohan,et al.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.

[44]  R. Terry Management of patients with atypical squamous cells of undetermined significance (ASCUS) on Papanicolaou smears , 1996, The Journal of the American Osteopathic Association.